{"entity":{"id":"morphosys","kind":"company","name":"MorphoSys (Novartis)","aka":[],"tldr":"German antibody company that acquired Constellation's BET inhibitor pelabresib and was itself bought by Novartis in 2024.","summary":"MorphoSys, based in Planegg near Munich, was the German antibody company that developed tafasitamab and acquired Constellation Pharmaceuticals for the BET inhibitor pelabresib, before Novartis bought it in 2024; OnCo marks the record as historic. Tafasitamab, sold as Monjuvi, is a CD19 antibody for diffuse large B-cell lymphoma whose rights moved to Incyte, and pelabresib, acquired with Constellation in 2021, was studied in myelofibrosis in the MANIFEST-2 trial. OnCo links it to diffuse large B-cell lymphoma, to CD19 as a target, to epigenetic drugs and monoclonal antibodies, and to Novartis. Whether pelabresib justifies the price Novartis paid is the question that outlived the company. Tafasitamab has its own page.","status":"historic","asOf":"2026-09-04","links":[{"label":"Official website","url":"https://www.morphosys.com"}],"tags":[],"related":[],"cancers":["dlbcl"],"sections":["epigenetics","immunotherapy"],"technologies":["epigenetic-drugs","monoclonal-antibody"],"targets":["cd19"],"drugs":[],"companies":["novartis"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Planegg","country":"DE","companyType":"biotech","website":"https://www.morphosys.com","investors":[],"funding":[]},"route":"/companies/morphosys/","neighbours":{"cancer":[{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"}],"section":[{"id":"epigenetics","kind":"section","name":"Epigenetic & Transcriptional Therapy","route":"/fronts/epigenetics/"},{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"technology":[{"id":"epigenetic-drugs","kind":"technology","name":"Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET)","route":"/technologies/epigenetic-drugs/"},{"id":"monoclonal-antibody","kind":"technology","name":"Monoclonal antibodies","route":"/technologies/monoclonal-antibody/"}],"target":[{"id":"cd19","kind":"target","name":"CD19","route":"/targets/cd19/"}],"company":[{"id":"novartis","kind":"company","name":"Novartis","route":"/companies/novartis/"}],"drug":[{"id":"tafasitamab","kind":"drug","name":"Tafasitamab","route":"/drugs/tafasitamab/"}],"trial":[{"id":"l-mind","kind":"trial","name":"L-MIND","route":"/trials/l-mind/"},{"id":"manifest-2","kind":"trial","name":"MANIFEST-2","route":"/trials/manifest-2/"}],"roadmap":[{"id":"epigenetics-roadmap","kind":"roadmap","name":"Epigenetic therapy roadmap: loosening silenced genes → mutation-specific enzymes → editing the epigenome","route":"/roadmaps/epigenetics-roadmap/"}]}}